Angany Inc. news
Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in San Diego, California between June 13th and 16th.
ANGANY’s primary focus is the development of therapeutic vaccines, leveraging the unique immunogenicity and safety profile of its plant-based eB
Louis-Philippe Vézina, CEO of Angany Inc. and Douglas Hein, President of Lincoln Diagnostics Inc. announce the commitment of their respective companies to collaborate on Angany’s outreach to US allergists. A formal agreement to this effect was signed earlier this year.
Angany introduces a new approach to allergy immunotherapy based on translational science and designed to overcome the limits of current desensitization approaches. Millions of years of ev
Dr Louis-Philippe Vézina Dr Véronique Gomord (respectively CEO and CSO of Angany), and Pr. Rogier W. Sanders and Dr Marit van Gils of University Medical Centers in Amsterdam (Amsterdam UMC) announce today significant advances made in the accelerated development of a preventive and curative product based on highly potent neutralizing monoclonal antibodies (NAbs) against the SARS-CoV-02 virus and its variants.
The new variants are a growing threat. NAbs-based products can